Content about Candidiasis

January 31, 2013
Monistat survey: 75% of women experience yeast infections, but misconceptions persist

Research has shown that 3-in-4 women will experience candidiasis, more commonly known as a vaginal yeast infection, and 67% are embarrassed by it, Insight Pharmaceuticals announced, citing an independent survey commissioned for Monistat.

TREVOSE, Pa. — Research has shown that three in four women will experience candidiasis, more commonly known as a vaginal yeast infection, and 67% are embarrassed by it, Insight Pharmaceuticals announced Wednesday, citing an independent survey commissioned for Monistat.

January 24, 2013
Perrigo, Ther-Rx announce availability of Gynazole-1

Perrigo and a subsidiary of K-V Pharmaceutical Co. have launched a new drug for yeast infections in women, the two companies said.

ST. LOUIS — Perrigo and a subsidiary of K-V Pharmaceutical Co. have launched a new drug for yeast infections in women, the two companies said.

Perrigo and Ther-Rx Corp. announced the availability of Gynazole-1 (butoconazole nitrate vaginal cream) in the 2% strength for treating yeast infections in nonpregnant women.

Ther-Rx has a partnership with Perrigo to manufacture the drug.

May 23, 2012
FDA approves treatment for vaginal fungus infections

The Food and Drug Administration has approved a generic treatment made by Perrigo for fungal infections of the vagina, the company said.

ALLEGAN, Mich. — The Food and Drug Administration has approved a generic treatment made by Perrigo for fungal infections of the vagina, the company said.

Perrigo announced the approval of butoconazole nitrate 2% vaginal cream, a generic version of KV Pharmaceutical's Gynazole-1, used to treat vulvovaginal candidiasis, an infection caused by Candida fungus. KV voluntarily discontinued selling the drug in January 2009 due to manufacturing problems.

March 21, 2011
Hi-Tech Pharmacal acquires candidiasis treatment

Generic drug maker Hi-Tech Pharmacal has acquired the rights to a drug for mouth infections, the company said Monday.

AMITYVILLE, N.Y. — Generic drug maker Hi-Tech Pharmacal has acquired the rights to a drug for mouth infections, the company said Monday.

Hi-Tech said it acquired nystatin oral suspension from Bausch & Lomb for an undisclosed sum. The drug is used to treat candidiasis, a fungal infection, in the mouth.

The market for the drug is $23 million, according to IMS Health.

September 8, 2010
Many young women may be mistreating yeast infections, study finds

According to a recent survey of women ages 18 to 24 years commissioned by the...

SKILLMAN, N.J. According to a recent survey of women ages 18 to 24 years commissioned by the Monistat brand, 61% of young women are unsure about which, if any, over-the-counter products can cure a yeast infection.

 

"Many women don't realize that once they've identified they have a yeast infection, they can easily treat it on their own terms," stated Suzanne Gilberg-Lenz, a board-certified OB/GYN who practices in Beverly Hills, Calif., and a partner in the Monistat survey.

 

 

June 2, 2010
Perrigo receives FDA approval for generic Monistat-1 Combination Pack

Perrigo on Thursday announced that it has received final approval from the Food and Drug...

March 8, 2010
Lake Consumer Products develops over-the-counter bacterial vaginosis treatment

Lake Consumer Products last week launched vH essentials BV treatment, a homeopathic vaginal tablet that...

JACKSON, Wis. Lake Consumer Products last week launched vH essentials BV treatment, a homeopathic vaginal tablet that provides relief from the odor, discharge and discomfort often associated with bacterial vaginosis.

According to the company, vH essentials BV treatment is the first over-the-counter BV symptom treatment product to be widely distributed through retail.